Rayyan vs Iris.ai (2026)

Rayyan

by Rayyan

Iris.ai

by Iris.ai

Pros

• ✓Academic-friendly pricing makes systematic review tools accessible where enterprise alternatives cannot: the permanent Free tier (3 reviews, 2 reviewers), Essential tier at $4.99/seat/month annual, and Advanced at $8.33/seat/month annual sit substantially below Covidence ($149+/month) and DistillerSR (custom pricing), removing cost as a barrier for graduate students and early-career researchers.
• ✓AI duplicate detection is widely regarded as best-in-category for systematic reviews: Rayyan deduplication is consistently cited as a primary reason researchers choose the platform over alternatives, reducing time on manual deduplication in large citation sets from PubMed, Scopus, and Web of Science exports.
• ✓1M+ researcher global installed base and university library endorsements provide strong community validation: library research guides at University of Hawaii, University of Mississippi, and multiple major institutions recommend Rayyan, and a PMC/NIH peer-reviewed study confirms 97-99% AI screening sensitivity for the Predictor engine.

Limitations

• ⚠Less depth than enterprise systematic review platforms: Rayyan is well-suited for academic and individual systematic review but lacks the workflow customization, advanced audit trails, and enterprise-grade reporting that Covidence or DistillerSR provide for high-stakes regulatory and clinical evidence synthesis workflows.
• ⚠Mobile free-tier friction and unexpected collaborator costs: Google Play reviewers report the 100-decision mobile screening limit on the free tier as a meaningful constraint, and invited collaborators on reviews where only the owner holds a paid subscription can face unexpected payment requirements to complete their screening tasks.
• ⚠Specialized for systematic reviews with no literature discovery or citation analysis: Rayyan covers evidence synthesis workflow (screening, deduplication, PRISMA) but lacks the deeper literature search of Undermind ($16/month annual), citation context analysis of Scite.ai ($12/month annual), or open-web synthesis of Gemini Deep Research.

Pros

• ✓Named enterprise adoption across Fortune 500 and government organizations: Mercedes-Benz, ArcelorMittal, USDA, Max Planck Gesellschaft, and Springer Nature appear on the official vendor homepage, providing procurement validation that is rare in the regulated enterprise AI infrastructure category.
• ✓Three-product architecture covers the full data-to-AI lifecycle: Axion handles data preparation into AI-ready intelligence, Neuralith powers the enterprise knowledge graph engine, and RSpace delivers precision R&D intelligence, providing end-to-end coverage that fragmented stacks requiring separate vendors for data preparation and AI agent deployment cannot match.
• ✓Ten-year track record from 2015 through multiple product pivots demonstrates operational maturity: the evolution from academic research AI through scientific language models to Agentic RAG-As-A-Services shows sustained development velocity and enterprise customer retention that AI challengers founded after 2020 cannot replicate.

Limitations

• ⚠No public independent review trail creates procurement friction: the G2 listing was removed in 2026, Trustpilot returns 404, and no Capterra presence exists, making third-party validation outside the vendor-provided homepage customer logos difficult; tools such as Elicit ($12/month) and SciSpace ($12/month) offer G2-verified reviews for procurement teams requiring independent evidence.
• ⚠Named integration depth is not published in official documentation: the Agentic RAG positioning implies enterprise data connectivity, but specific native integrations with SAP, Salesforce, Veeva Vault, SharePoint, PubMed, or Scopus are not confirmed, requiring sales-led scoping before integration depth can be evaluated.
• ⚠Enterprise-only entry with no self-serve evaluation path excludes individual researchers, academic teams, and smaller organizations: the platform requires sales-led engagement, custom data engineering, and sustained implementation investment with no trial access, while Elicit ($12/month) and SciSpace ($12/month) serve research use cases at a fraction of the cost and without implementation complexity.